Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 7:8:617378.
doi: 10.3389/fmed.2021.617378. eCollection 2021.

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

Silvia Corcione  1   2 , Tommaso Lupia  1 , Francesco Giuseppe De Rosa  1
Affiliations

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

Silvia Corcione et al. Front Med (Lausanne). .

Abstract

In past decade, cephalosporins have developed significantly, and data regarding novel cephalosporins (i.e., ceftobiprole, ceftaroline, ceftolozane/tazobactam, ceftazidime/avibactam, and cefiderocol) within septic and bacteremic subjects are rising. These compounds generally offer very promising in vitro microbiological susceptibility, although the variability among gram-negative and -positive strains of different cohorts is noticed in the literature. We require further pharmacological data to measure the best dose in order to prevent sub-therapeutic drug levels in critically ill patients. These new compounds in theory are the sparing solution in the Enterobacteriales infection group for different antimicrobial classes such as aminoglycosides notably within endovascular and GNB-bacteremias, as well as colistin and carbapenem-sparing strategies, favoring good safety profile molecules. Moreover, new cephalosporins are the basis for the actual indications to open up new and exciting prospects for serious infections in the future. In future, patients will be addressed with the desirable approach to sepsis and serious infections in terms of their clinical situation, inherent features of the host, the sensitivity profile, and local epidemiology, for which evidence of the use of new cephalosporin in the treatment of severe infections will fill the remaining gaps.

Keywords: blood-stream infections; cephalosporin; multi-drug resistant bacteria; sepsis; severe infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Present and future perspectives within novel cephalosporins compounds.
See this image and copyright information in PMC

References

    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. (2013) 369:2063. 10.1056/NEJMc1312359 - DOI - PubMed
    1. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. . Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. (2020) 395:200–11. 10.1016/S0140-6736(19)32989-7 - DOI - PMC - PubMed
    1. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. (2018) 392:75–87. 10.1016/S0140-6736(18)30696-2 - DOI - PubMed
    1. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. . Sepsis: a roadmap for future research. Lancet Infect Dis. (2015) 15:581–614. 10.1016/S1473-3099(15)70112-X - DOI - PubMed
    1. Lupia T, Corcione S, Mornese Pinna S, De Rosa FG. New cephalosporins for the treatment of pneumonia in internal medicine wards. J Thorac Dis. (2020) 12:3747–63. 10.21037/jtd-20-417 - DOI - PMC - PubMed